Allos Therapeutics to provide FOLOTYN trial results in ESMO Congress Allos Therapeutics.

Kelly, University of Kansas, Kansas Town/US Abstract Number: LBA17 Location: Upper body tumors II, Gold Hall.. Allos Therapeutics to provide FOLOTYN trial results in ESMO Congress Allos Therapeutics, Inc. ‘We believe these are important results for the cancer community – generating data on the efficacy and protection profile for FOLOTYN in this treatment setting where there remains a higher unmet need – and so are delighted that the ESMO Congress offers accepted these data as a late-breaking abstract to be highlighted within an oral presentation. The aim of the trial was to estimate the efficacy of FOLOTYN in comparison to that of erlotinib as assessed by general survival. The principal endpoint of the trial was general survival.This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an unbiased news service editorially, is a scheduled plan of the Kaiser Family Foundation, a nonpartisan healthcare policy research business unaffiliated with Kaiser Permanente.

$10 million in CDC grants awarded to overcome hospital-acquired infections The Hill: CDC Awards $10 Million In FIGHT Hospital-Acquired Infections The Centers for Disease Control and Avoidance on Monday awarded $10 million to five medical centers to build up and test new methods to combating infections acquired in hospitals and other care settings.